Natalizumab Postinfusion Reactions Rare; Is Monitoring Necessary?



Several studies show these infusion reactions are very rare and mild; the required monitoring presents particular risk during the COVID pandemic.
Medscape Medical News

Source link

Comments are closed, but trackbacks and pingbacks are open.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy